Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza
12:00pm, Tuesday, 13'th Sep 2022 GlobeNewswire Inc.
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform designed to help transform the standard of care for seasonal and pandemic influenza prevention
Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
12:00pm, Tuesday, 06'th Sep 2022 GlobeNewswire Inc.
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patie
Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
08:00am, Tuesday, 06'th Sep 2022
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patient
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
11:25pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 32.14% and 14.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
09:16pm, Tuesday, 09'th Aug 2022 GlobeNewswire Inc.
SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patien
Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
09:04pm, Tuesday, 09'th Aug 2022
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 32.14% and 14.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Monday, 08'th Aug 2022 Zacks Investment Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates
02:45pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Xoma (XOMA) delivered earnings and revenue surprises of -381.82% and 88.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biogen Inc. (BIIB) Q2 Earnings and Revenues Surpass Estimates
12:25pm, Wednesday, 20'th Jul 2022 Zacks Investment Research
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 28.36% and 4.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock
07:36pm, Thursday, 12'th May 2022 Benzinga
U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch.
Cidara confirmed tha
Read Why HC Wainwright Lowered Price Target On This Small Biotech Stock
03:47pm, Thursday, 12'th May 2022
U.S. marketing application filing for Cidara Therapeutics Inc's (NASDAQ: CDTX) rezafungin remains on track for mid-2022, setting up a potential early 2023 approval and launch. Cidara confirmed tha
Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates
09:35pm, Wednesday, 11'th May 2022 Zacks Investment Research
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
08:13pm, Wednesday, 11'th May 2022 GlobeNewswire Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patient
Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates
06:49pm, Wednesday, 11'th May 2022
Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -3.85% and 3.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
